Clinical Trial Update: Re-treatment 225Ac-J591 for mCRPC [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) trial evaluating re-treatment with Actinium-225 labeled J591 for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 225Ac-J591 (Actinium-225-labeled J591)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: COMPLETED